Company profile for Castle Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Our tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating persona...
Castle Biosciences develops and commercializes diagnostic and prognostic tests for dermatologic cancers. Our tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions. We believe that the traditional approach to developing a treatment plan for dermatologic cancers using clinical and pathology factors alone is inadequate, and can be improved by incorporating personalized genomic information. All of our tests are performed in a CLIA-certified, CAP-accredited clinical laboratory.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
820 S. Friendswood Drive, Suite 201 Friendswood, TX 77546
Telephone
Telephone
866-788-9007
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/19/3208395/0/en/Castle-Biosciences-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

GLOBENEWSWIRE
19 Dec 2025

https://www.globenewswire.com/news-release/2025/12/12/3204559/0/en/Systematic-Review-and-Meta-Analysis-Confirms-TissueCypher-Outperforms-Traditional-Pathology-or-Clinical-Factors-Alone-to-Identify-Patients-at-Increased-Risk-of-Developing-Esophagea.html

GLOBENEWSWIRE
12 Dec 2025

https://www.globenewswire.com/news-release/2025/11/17/3188966/0/en/Castle-Biosciences-Earns-a-Houston-Chronicle-Top-Workplaces-Award-for-the-Fifth-Consecutive-Year.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/14/3188185/0/en/New-Data-Confirms-Performance-of-DecisionDx-Melanoma-to-Identify-Patients-with-Less-Than-Five-Percent-Risk-of-Sentinel-Lymph-Node-Positivity.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/11/11/3185287/0/en/Castle-Biosciences-to-Present-at-the-Piper-Sandler-37th-Annual-Healthcare-Conference.html

GLOBENEWSWIRE
11 Nov 2025

https://www.globenewswire.com/news-release/2025/11/03/3179800/0/en/Castle-Biosciences-Launches-AdvanceAD-Tx-to-Help-Guide-Systemic-Treatment-Decision-Making-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis.html

GLOBENEWSWIRE
03 Nov 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty